USA |NASDAQ |USD
Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
---|---|---|---|---|
Aug 3, 2022 | Jun 2022 | - | - | $-0.66 |
Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
---|---|---|---|---|
Aug 3, 2022 | Jun 2022 | - | - | $54.02M |
Bridgebio Pharma, Inc's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 8 | $-3.67 | $-5.03 | $-2.69 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Dec 2022 | 1 / 2 | $-3.58 | $-3.53 | $-3.98 |
Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
---|
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 8 | $115.99M | $18.52M | $316.75M |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
May 4, 2022 | Mar 2022 | $-1.11 | - | - |
Feb 24, 2022 | Dec 2021 | $-0.87 | $-1.01 | -16.09% |
Nov 4, 2021 | Sep 2021 | $-0.93 | $-1.06 | -13.89% |
Aug 5, 2021 | Jun 2021 | $-0.97 | $-0.66 | 32.11% |
May 6, 2021 | Mar 2021 | $-0.81 | $-1.18 | -45.27% |
Feb 25, 2021 | Dec 2020 | $-0.85 | $-1.01 | -19.29% |
Nov 5, 2020 | Sep 2020 | $-0.97 | $-0.98 | -0.68% |
Aug 11, 2020 | Jun 2020 | $-0.80 | $-1.03 | -28.40% |
May 13, 2020 | Mar 2020 | $-0.71 | $-0.78 | -9.14% |
Mar 2, 2020 | Dec 2019 | $-0.71 | $-0.62 | 12.22% |
Nov 7, 2019 | Sep 2019 | $-0.55 | $-0.51 | 7.73% |
Aug 14, 2019 | Jun 2019 | $-0.55 | $-0.56 | -1.54% |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Feb 24, 2022 | Dec 2021 | $-3.65 | $-3.91 | - |
Feb 25, 2021 | Dec 2020 | $-3.54 | $-3.80 | - |
Mar 2, 2020 | Dec 2019 | $-2.87 | $-1.69 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
May 4, 2022 | Mar 2022 | - | - | - |
Feb 24, 2022 | Dec 2021 | $30.91M | $12.89M | 0.42% |
Nov 4, 2021 | Sep 2021 | $18.74M | $2.34M | 0.13% |
Aug 5, 2021 | Jun 2021 | $34.84M | $54.02M | 1.55% |
May 6, 2021 | Mar 2021 | $30.48M | $462.00K | 0.02% |
Feb 25, 2021 | Dec 2020 | $16.93M | $122.00K | 0.01% |
Nov 5, 2020 | Sep 2020 | $8.60M | $8.13M | 0.95% |
Aug 11, 2020 | Jun 2020 | $0.00 | $0.00 | - |
May 13, 2020 | Mar 2020 | $0.00 | $13.82M | - |
Mar 2, 2020 | Dec 2019 | $0.00 | $13.82M | - |
Nov 7, 2019 | Sep 2019 | $0.00 | $26.74M | - |
Aug 14, 2019 | Jun 2019 | $0.00 | $0.00 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Feb 24, 2022 | Dec 2021 | $110.40M | $69.72M | -36.85% |
Feb 25, 2021 | Dec 2020 | $24.13M | $8.25M | -65.81% |
Mar 2, 2020 | Dec 2019 | $0.00 | $40.56M | - |
BBIO's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.
Bridgebio Pharma, Inc's previous earnings date was May 4, 2022 for its fiscal quarter ended Mar 31, 2022.
Bridgebio Pharma, Inc's previous annual earnings date was Feb 24, 2022 for its fiscal year ended Dec 31, 2021.
BBIO's earnings per share (EPS) was $-3.91, missing the consensus analysts forecast of $-3.65 by 7.12% , and lower than the previous year's EPS (Dec 2020) by 2.89%.
Revenues were $69.72M, worse than the forecast of $110.40M by -36.85%, and up by 745.14% from previous year's revenue.
The company reported a net income of $-562.54M.
Bridgebio Pharma, Inc reported a free cash flow of $-511.18M for its fiscal year, compared to $-407.23M a year ago.
The company ended the fiscal year with $1.73B in total debt, an increase of 258.79% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.